X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5044) 5044
Publication (395) 395
Newsletter (127) 127
Book Review (38) 38
Book Chapter (23) 23
Magazine Article (17) 17
Newspaper Article (13) 13
Book / eBook (9) 9
Conference Proceeding (4) 4
Trade Publication Article (3) 3
Dissertation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4116) 4116
male (2228) 2228
female (2114) 2114
hematology (2067) 2067
polycythemia-vera (1998) 1998
index medicus (1946) 1946
middle aged (1890) 1890
aged (1619) 1619
essential thrombocythemia (1601) 1601
adult (1489) 1489
polycythemia vera (1217) 1217
mutation (1080) 1080
oncology (1036) 1036
janus kinase 2 - genetics (947) 947
polycythemia vera - diagnosis (931) 931
polycythemia (855) 855
myelofibrosis (823) 823
myeloproliferative disorders (821) 821
aged, 80 and over (764) 764
diagnosis (703) 703
polycythemia vera - complications (678) 678
polycythemia vera - genetics (591) 591
myeloproliferative neoplasms (577) 577
diagnosis, differential (551) 551
thrombosis (532) 532
tyrosine kinase jak2 (513) 513
myeloproliferative disorders - genetics (512) 512
risk factors (504) 504
leukemia (488) 488
jak2 (455) 455
prognosis (449) 449
primary myelofibrosis (411) 411
polycythemia vera - blood (409) 409
adolescent (406) 406
genetic aspects (394) 394
thrombocythemia, essential - genetics (393) 393
myeloproliferative disorders - diagnosis (381) 381
care and treatment (378) 378
tumors (378) 378
polycythemia vera - pathology (372) 372
medicine, general & internal (364) 364
hydroxyurea (363) 363
myeloid metaplasia (351) 351
research (344) 344
polycythemia vera - therapy (335) 335
primary myelofibrosis - genetics (334) 334
polycythemia vera - drug therapy (323) 323
chronic myeloproliferative disorders (318) 318
thrombocythemia, essential - diagnosis (316) 316
retrospective studies (311) 311
analysis (310) 310
bone marrow - pathology (307) 307
medicine & public health (306) 306
primary myelofibrosis - diagnosis (301) 301
disorders (295) 295
polycythemia - diagnosis (284) 284
young adult (280) 280
hemic and lymphatic diseases (278) 278
treatment outcome (273) 273
pathology (270) 270
hematocrit (248) 248
jak2 v617f mutation (248) 248
cancer (246) 246
hydroxyurea - therapeutic use (236) 236
janus kinase 2 (236) 236
disease (232) 232
primary myelofibrosis - pathology (231) 231
thrombocythemia, essential - complications (228) 228
risk (227) 227
survival (227) 227
erythropoietin (220) 220
hematology, oncology and palliative medicine (220) 220
myeloproliferative disorders - pathology (219) 219
health aspects (218) 218
thrombocythemia, essential - pathology (216) 216
follow-up studies (215) 215
therapy (211) 211
child (208) 208
platelet count (208) 208
bone marrow (207) 207
animals (206) 206
international working group (200) 200
chronic disease (198) 198
idiopathic myelofibrosis (198) 198
thrombosis - etiology (196) 196
patients (194) 194
disease progression (193) 193
classification (190) 190
abridged index medicus (186) 186
thrombocythemia, essential - drug therapy (184) 184
gene mutations (183) 183
medical research (179) 179
thrombocytosis (178) 178
management (177) 177
myeloproliferative neoplasm (177) 177
erythrocytosis (173) 173
acute myeloid-leukemia (171) 171
alleles (170) 170
blood (170) 170
polycythemia - etiology (169) 169
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4671) 4671
German (163) 163
French (121) 121
Russian (64) 64
Spanish (40) 40
Japanese (37) 37
Polish (21) 21
Italian (18) 18
Hungarian (12) 12
Korean (11) 11
Chinese (10) 10
Dutch (9) 9
Swedish (9) 9
Czech (6) 6
Danish (6) 6
Norwegian (6) 6
Romanian (6) 6
Turkish (6) 6
Portuguese (3) 3
Croatian (2) 2
Serbian (2) 2
Slovak (2) 2
Bulgarian (1) 1
Finnish (1) 1
Hebrew (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood Cells, Molecules and Diseases, ISSN 1079-9796, 02/2020, Volume 80, p. 102355
A low erythropoietin (EPO) level is a minor diagnostic criterion for polycythemia vera (PV). Controversies exist regarding the diagnostic value of a low EPO... 
Polycythemia vera | Myelofibrosis | Erythropoietin | Myeloproliferative neoplasm
Journal Article
Turkish Journal of Medical Sciences, ISSN 1300-0144, 2018, Volume 48, Issue 4, pp. 698 - 710
Journal Article
Turkish journal of medical sciences, 08/2018, Volume 48, Issue 4, p. 698
Very important developments related to polycythemia vera (PV) have occurred during the last two decades. The discovery of Janus kinase (JAK) 2 mutations has... 
Prognosis | Humans | Janus Kinase 2 - genetics | Polycythemia Vera - genetics | Disease Management | Polycythemia Vera - therapy | Mutation - genetics | Polycythemia Vera - diagnosis | Disease Progression | Janus Kinase 2 - antagonists & inhibitors | Polycythemia Vera - physiopathology
Journal Article
American Journal of Hematology, ISSN 0361-8609, 01/2017, Volume 92, Issue 1, pp. 94 - 108
Disease overview Polycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and... 
ACUTE-LEUKEMIA | JAK2(V617F) MUTATION | MYELOFIBROSIS RESEARCH | LOW-DOSE ASPIRIN | LONG-TERM SURVIVAL | MYELOPROLIFERATIVE NEOPLASMS | CALRETICULIN MUTATIONS | DEFINED ESSENTIAL THROMBOCYTHEMIA | HEMATOLOGY | INTERFERON-ALPHA THERAPY | INTERNATIONAL WORKING GROUP | Primary Myelofibrosis - mortality | Humans | Polycythemia Vera - blood | Polycythemia Vera - genetics | Primary Myelofibrosis - pathology | Thrombocythemia, Essential - genetics | Calreticulin - genetics | Aspirin - administration & dosage | Erythropoietin - blood | Thrombocytosis - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aspirin - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Thrombocytosis - pathology | Thrombocythemia, Essential - drug therapy | Primary Myelofibrosis - diagnosis | Diagnosis, Differential | Risk Assessment | Interferon-alpha - therapeutic use | Janus Kinase 2 - genetics | Hydroxyurea - administration & dosage | Thrombocythemia, Essential - blood | Polycythemia Vera - diagnosis | Thrombocytosis - diagnosis | Interferon-alpha - administration & dosage | Receptors, Thrombopoietin - genetics | Thrombocythemia, Essential - diagnosis | Hydroxyurea - therapeutic use | Polycythemia Vera - drug therapy | Mutation | Erythropoietin | Polycythemia | Leukemia | Diagnosis | Tumor proteins | Thrombosis | Risk factors | Blood clot
Journal Article
American Journal of Hematology, ISSN 0361-8609, 06/2013, Volume 88, Issue 6, pp. 507 - 516
Disease Overview Polycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) primarily characterized by erythrocytosis and... 
Thrombocytosis - blood | Humans | Risk Factors | Polycythemia Vera - blood | Survival Analysis | Polycythemia Vera - therapy | Polycythemia Vera - diagnosis | Thrombocytosis - therapy | Thrombocytosis - diagnosis | Aspirin | Erythropoietin | Anemia | Polycythemia | Leukemia | Development and progression | Hydroxyurea | Diagnosis | Biological response modifiers | Risk factors
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 02/2017, Volume 129, Issue 6, pp. 680 - 692
Journal Article